These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 19384573

  • 1. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
    Kasture S, Pontis S, Pinna A, Schintu N, Spina L, Longoni R, Simola N, Ballero M, Morelli M.
    Neurotox Res; 2009 Feb; 15(2):111-22. PubMed ID: 19384573
    [Abstract] [Full Text] [Related]

  • 2. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A, Tronci E, Schintu N, Simola N, Volpini R, Pontis S, Cristalli G, Morelli M.
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model.
    Yadav SK, Prakash J, Chouhan S, Westfall S, Verma M, Singh TD, Singh SP.
    Neurochem Int; 2014 Jan; 65():1-13. PubMed ID: 24333323
    [Abstract] [Full Text] [Related]

  • 4. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF, Leo G, Vergoni AV, Martínez E, Hockemeyer J, Lluis C, Franco R, Fuxe K, Ferré S.
    Brain Res Bull; 2004 Aug 30; 64(2):155-64. PubMed ID: 15342103
    [Abstract] [Full Text] [Related]

  • 5. Comparative evaluation of extract of Bacopa monnieri and Mucuna pruriens as neuroprotectant in MPTP model of Parkinson’s disease.
    Singh B, Pandey S, Verma R, Ansari JA, Mahdi AA.
    Indian J Exp Biol; 2016 Nov 30; 54(11):758-66. PubMed ID: 30179419
    [Abstract] [Full Text] [Related]

  • 6. A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias.
    Lieu CA, Kunselman AR, Manyam BV, Venkiteswaran K, Subramanian T.
    Parkinsonism Relat Disord; 2010 Aug 30; 16(7):458-65. PubMed ID: 20570206
    [Abstract] [Full Text] [Related]

  • 7. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, Morelli M.
    Eur J Pharmacol; 2007 Jul 02; 566(1-3):94-102. PubMed ID: 17445798
    [Abstract] [Full Text] [Related]

  • 8. Levodopa-Reduced Mucuna pruriens Seed Extract Shows Neuroprotective Effects against Parkinson's Disease in Murine Microglia and Human Neuroblastoma Cells, Caenorhabditis elegans, and Drosophila melanogaster.
    Johnson SL, Park HY, DaSilva NA, Vattem DA, Ma H, Seeram NP.
    Nutrients; 2018 Aug 22; 10(9):. PubMed ID: 30131460
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mucuna pruriens Seed Aqueous Extract Improved Neuroprotective and Acetylcholinesterase Inhibitory Effects Compared with Synthetic L-Dopa.
    Kamkaen N, Chittasupho C, Vorarat S, Tadtong S, Phrompittayarat W, Okonogi S, Kwankhao P.
    Molecules; 2022 May 13; 27(10):. PubMed ID: 35630617
    [Abstract] [Full Text] [Related]

  • 11. Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile.
    Cassani E, Cilia R, Laguna J, Barichella M, Contin M, Cereda E, Isaias IU, Sparvoli F, Akpalu A, Budu KO, Scarpa MT, Pezzoli G.
    J Neurol Sci; 2016 Jun 15; 365():175-80. PubMed ID: 27206902
    [Abstract] [Full Text] [Related]

  • 12. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
    Pinna A, Pontis S, Borsini F, Morelli M.
    Synapse; 2007 Aug 15; 61(8):606-14. PubMed ID: 17476684
    [Abstract] [Full Text] [Related]

  • 13. Gynostemma pentaphyllum Ethanolic Extract Protects Against Memory Deficits in an MPTP-Lesioned Mouse Model of Parkinson's Disease Treated with L-DOPA.
    Kim KS, Zhao TT, Shin KS, Park HJ, Cho YJ, Lee KE, Kim SH, Lee MK.
    J Med Food; 2017 Jan 15; 20(1):11-18. PubMed ID: 28005447
    [Abstract] [Full Text] [Related]

  • 14. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun 15; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 15. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.
    Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Van der Giessen R, Lees AJ.
    J Neurol Neurosurg Psychiatry; 2004 Dec 15; 75(12):1672-7. PubMed ID: 15548480
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Neuroprotective effects of the antiparkinson drug Mucuna pruriens.
    Manyam BV, Dhanasekaran M, Hare TA.
    Phytother Res; 2004 Sep 15; 18(9):706-12. PubMed ID: 15478206
    [Abstract] [Full Text] [Related]

  • 18. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A, Ko WK, Costa G, Tronci E, Fidalgo C, Simola N, Li Q, Tabrizi MA, Bezard E, Carta M, Morelli M.
    Mov Disord; 2016 Apr 15; 31(4):501-11. PubMed ID: 26871939
    [Abstract] [Full Text] [Related]

  • 19. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Naskar A, Prabhakar V, Singh R, Dutta D, Mohanakumar KP.
    J Pineal Res; 2015 Apr 15; 58(3):262-74. PubMed ID: 25626558
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.